| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1938 | |
| Phytochemical name or plant extracts | Astragaloside IV | |
| PMID | 30243825 | |
| Literature evidence | CONCLUSIONS: Our results proved that HQ and its main bioactive compounds could induce the P-gp and BCRP expression through the activation of the Nrf2-mediated signaling pathway. | |
| IUPAC name | (2R,3R,4S,5S,6R)-2-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-14-hydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-9-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol | |
| Phytochemicals’ class or type of plant extracts | Triterpenoid | |
| Source of phytochemicals or plant Extracts | Astragali radix | |
| Geographical availability | China | |
| Plant parts | Root | |
| Other cancers | Breast cancer | |
| Target gene or protein | P-gp, BCRP, Nrf2 | |
| Gene or Protein evidence | HQ, AS-IV, CS and FMNT significantly upregulated the P-gp and BCRP expression in the liver of wild-type mice. The induction was significantly reversed in the Nrf2-/- mice. HQ and these compounds significantly increased the Nrf2 expression in wild-type mice. HQ and these compounds also markedly enhanced the ARE-luciferin activity and promoted the nuclear translocation of Nrf2 in cells. | |
| Target pathways | PI3K/AKT/mTOR signaling pathway | |
| IC50 | NA | |
| Potency | Our results proved that HQ and its main bioactive compounds could induce the P-gp and BCRP expression through the activation of the Nrf2-mediated signaling pathway. | |
| Cell line/ mice model | Wild-type C57BL/6 mice | |
| Additional information | Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1/MAPK signaling. | |
| PubChem ID | 13943297 | |
| Additional PMIDs | 31762993 30243825 27930970 | |
| Additional sources of information | NA | |
| Safety | NA |